1. In Vivo
  2. >>Global Vision

Speedel Group: Strings Attached? No Problem

 
• By Chris Morrison

Speedel Group sets itself apart from many in-licensing companies by offering partners a call-back option on development projects. This, plus its tight focus on renin inhibition and Big Pharma savvy management have allowed the group to build a pipeline. Critics say the model restricts Speedel's upside. But the success of its first project, Novartis' Phase III SPP100, and one of Europe's largest private financings of 2003 suggest the group has a strong chance of proving them wrong.

In 1998, one of Novartis AG 's top late-stage development prospects, the first-in-class Phase III renin inhibitor aliskiren, was an early-stage project that didn't quite make the grade. Novartis didn't want to commit significant resources to develop the anti-hypertensive; renin inhibitors, although scientifically interesting, had failed to live up to their early promise—indeed more than 30 years after the blood pressure regulating renin-angiotensin system (RAS) was first pharmacologically tweaked by inhibiting angiotensin-converting enzyme (ACE), no renin inhibitors have made it to the market. (See Sidebar: The Renin-Angiotensin System.)

But neither did the Big Pharma, fresh from its formation after the March 1996 merger of Sandoz and Ciba-Geigy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

The Rise In China Deals: How International Biopharma Is Turning To China For Innovation

 
• By Joseph Haas, Mary Jo Laffler, and Nancy Pham

The rapid growth of Chinese biopharmas has led to increased dealmaking with the US and Europe, but that could be stifled by a potential new Trump Administration policy.

By The Numbers: Phase III Trials In China Skyrocket While Phase I Falls To Earth

 
• By Mainbayar Badarch

China has rapidly expanded its clinical trial footprint since 2015, driven by regulatory reforms and increased investment in pharma R&D. By 2023, it matched the US in trial volume. Oncology leads, but biologics are leading in momentum.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By Jo Shorthouse

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

More from In Vivo

US Tariffs And Geopolitical Tensions Push EU To New Trade Routes And Infrastructure Growth

 
• By Francesca Bruce

The EU is diversifying its trading partners, which means that new markets may open up to the pharmaceutical industry, countering transatlantic tensions.

Too Big To Refill? Pharma’s Race To Replace $300bn In Expiring Revenues

 
• By Daniel Chancellor

An extensive list of blockbuster drugs face patent expiry over the next six years, putting significant revenues at risk for major companies. While Eli Lilly and Novo Nordisk are reaping the rewards of GLP-1 successes, other large pharmas face steep challenges in closing their growth gaps.

Beyond Cebranopadol: Tris Pharma’s 25-Year Legacy In Drug Delivery Innovation

 
• By David Wild

Tris Pharma may be making headlines for its novel pain medication cebranopadol, but the New Jersey-based company's story extends far beyond a single asset.